Fam-trastuzumab deruxtecan-nxki is biosimilar.
Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate consisting of a humanized IgG1 monoclonal antibody (trastuzumab) covalently linked to a type I DNA topoisomerase inhibitor DXd (an exatecan derivative).
- TRADE NAME: Enhertu (Daiichi Sankyo)
- INDICATIONS:
Indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
- CLASS: Antibody-drug conjugate (ADC), Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: ~ 6 days
- FDA APPROVAL DATE: 12/20/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Page last updated 03/13/2026
